Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Tim M, Illidge"'
Autor:
Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A. H. Zeef, Antonia Banyard, Stephen J. Kitcatt, Eleanor J. Cheadle, Karoliina Tuomela, Swati Pendharkar, Aws Al-Deka, Beatrice Salerno, Sophie Raby, Ian G. Mills, Jamie Honeychurch, Tim M. Illidge
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTDespite breakthroughs in immune checkpoint inhibitors (ICI), the majority of tumors, including those poorly infiltrated by CD8+ T cells or heavily infiltrated by immunosuppressive immune effector cells, are unlikely to result in clinically me
Externí odkaz:
https://doaj.org/article/9f867c6013ac405080b84ec982759eae
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-11 (2020)
Abstract Radiotherapy (RT) is a highly effective anti-cancer therapy delivered to around 50–60% of patients. It is part of therapy for around 40% of cancer patients who are cured of their disease. Until recently, the focus of this anti-tumour effic
Externí odkaz:
https://doaj.org/article/ce5e0a6e8e0b40d4bae60f86c06ab34f
Autor:
Tim M. Illidge, Elizabeth H. Phillips, Nicholas Counsell, Ruth Pettengell, Peter W.M. Johnson, Dominic J. Culligan, Bilyana Popova, Laura Clifton-Hadley, Andrew McMillan, Peter Hoskin, Sally F. Barrington, John Radford
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 203-206 (2020)
Externí odkaz:
https://doaj.org/article/22a017ba18324963a873caf2b7ad3390
Autor:
Emma J Searle, Brian A Telfer, Debayan Mukherjee, Duncan M Forster, Barry R Davies, Kaye J Williams, Ian J Stratford, Tim M Illidge
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 12, Pp 1646-1659 (2017)
Abstract Radiotherapy is an important anti‐cancer treatment, but tumour recurrence remains a significant clinical problem. In an effort to improve outcomes further, targeted anti‐cancer drugs are being tested in combination with radiotherapy. Her
Externí odkaz:
https://doaj.org/article/94b34dde6bcb4bbb88dfef6a2ecc2928
Autor:
Tim M. Illidge, Jamie Honeychurch, Robert W. Wilkinson, Hazel Jones, Ross Stewart, Michelle Morrow, Edmund Poon, Ian J. Stratford, Eleanor J. Cheadle, Sherrie Jones, Conor McKenna, Grazyna Lipowska-Bhalla, Amy L. Adlard, Simon J. Dovedi
Supplemental figure 1: Gating strategy for determining tumor cell PD-L1 expression. Supplemental figure 2: Impact of low-dose fractionated RT on PD-L1 expression by CD11b+GR1Hi cells. Supplemental figure 3: Dual blockade of PD-1 and PD-L1 does not fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18798dd2b1411cce7bf46bf133395698
https://doi.org/10.1158/0008-5472.22403754.v1
https://doi.org/10.1158/0008-5472.22403754.v1
Autor:
Tim M, Illidge, Sam, Mayes, Ruth, Pettengell, Andrew T, Bates, Mike, Bayne, John A, Radford, W David J, Ryder, Steven, Le Gouill, Fabrice, Jardin, Jill, Tipping, Maureen, Zivanovic, Françoise, Kraeber-Bodere, Manuel, Bardies, Caroline, Bodet-Milin, Emmanuel, Malek, Damien, Huglo, Franck, Morschhauser
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(3)
We report an international, multicenter phase II trial to evaluate the efficacy and toxicity of fractionated (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of follicular lymphoma (FL).A total of 74 patients, with a median age of 61 years (r
Autor:
Eskian, Mahsa1,2, Khorasanizadeh, MirHojjat1,2, Zinzani, Pier Luigi3, Illidge, Tim M.4, Rezaei, Nima1,5,6 rezaei_nima@tums.ac.ir
Publikováno v:
International Reviews of Immunology. 2019, Vol. 38 Issue 2, p79-91. 13p.
Publikováno v:
British Journal of Cancer. 1/14/2003 Supplement 1, Vol. 88, p1-76. 76p.
Autor:
Colton, Madyson1 (AUTHOR), Cheadle, Eleanor J.1 (AUTHOR), Honeychurch, Jamie1 (AUTHOR), Illidge, Tim M.1,2 (AUTHOR) tim.illidge@manchester.ac.uk
Publikováno v:
Radiation Oncology. 11/4/2020, Vol. 15 Issue 1, pN.PAG-N.PAG. 1p.
Publikováno v:
British Journal of Radiology; Oct2016, Vol. 89 Issue 1066, p1-6, 6p, 1 Color Photograph